Eagle Pharmaceuticals Stock Analysis

EGRX Stock  USD 3.95  0.11  2.71%   
Eagle Pharmaceuticals is overvalued with Real Value of 3.46 and Target Price of 17.0. The main objective of Eagle Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Eagle Pharmaceuticals is worth, separate from its market price. There are two main types of Eagle Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Eagle Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Eagle Pharmaceuticals is usually not traded on Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day. Eagle Stock trading window is adjusted to America/New York timezone.
  
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eagle Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Eagle Stock please use our How to Invest in Eagle Pharmaceuticals guide.

Eagle Stock Analysis Notes

About 12.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.24. Some equities with similar Price to Book (P/B) outperform the market in the long run. Eagle Pharmaceuticals has Price/Earnings To Growth (PEG) ratio of 0.91. The entity had not issued any dividends in recent years. Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey. Eagle Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 102 people. To learn more about Eagle Pharmaceuticals call Scott Tarriff at 201 326 5300 or check out https://www.eagleus.com.

Eagle Pharmaceuticals Quarterly Total Revenue

64.65 Million

Eagle Pharmaceuticals Investment Alerts

Eagle Pharmaceuticals generated a negative expected return over the last 90 days
Eagle Pharmaceuticals has high historical volatility and very poor performance
Eagle Pharmaceuticals is unlikely to experience financial distress in the next 2 years
Over 82.0% of the company shares are held by institutions such as insurance companies
Latest headline from news.google.com: Eagle Pharmaceuticals, Inc. Sees Significant Decrease in Short Interest - Defense World

Eagle Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by Eagle Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
11th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View
30th of September 2023
Last Quarter Report
View

Eagle Largest EPS Surprises

Earnings surprises can significantly impact Eagle Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2016-08-09
2016-06-300.710.80.0912 
2015-11-11
2015-09-30-0.56-0.65-0.0916 
2014-05-14
2014-03-31-0.26-0.36-0.138 
View All Earnings Estimates

Eagle Pharmaceuticals Environmental, Social, and Governance (ESG) Scores

Eagle Pharmaceuticals' ESG score is a quantitative measure that evaluates Eagle Pharmaceuticals' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Eagle Pharmaceuticals' operations that may have significant financial implications and affect Eagle Pharmaceuticals' stock price as well as guide investors towards more socially responsible investments.

Eagle Pharmaceuticals Thematic Classifications

In addition to having Eagle Pharmaceuticals stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Pharmaceutical Products Idea
Pharmaceutical Products
USA Equities from Pharmaceutical Products industry as classified by Fama & French
Cancer Fighters Idea
Cancer Fighters
Public companies from health care and pharmaceutical sectors that are focused on fighting cancer

Eagle Stock Institutional Investors

Shares
Marshall Wace Asset Management Ltd2024-03-31
257.5 K
Two Sigma Advisers, Llc2024-03-31
236.3 K
Geode Capital Management, Llc2024-03-31
231.6 K
D. E. Shaw & Co Lp2024-03-31
219.8 K
State Street Corporation2024-03-31
213.7 K
Los Angeles Capital Management Llc2024-03-31
191.7 K
Assenagon Asset Management Sa2024-03-31
185.3 K
Goldman Sachs Group Inc2024-03-31
177.8 K
Dimensional Fund Advisors, Inc.2024-03-31
171.1 K
Nantahala Capital Management, Llc2024-03-31
1.3 M
Aigh Capital Management, Llc2024-03-31
1.2 M
Note, although Eagle Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Eagle Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 52.55 M.

Eagle Profitablity

The company has Profit Margin (PM) of 0.05 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.16 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.16.
Last ReportedProjected for Next Year
Return On Tangible Assets 0.13  0.14 
Return On Capital Employed 0.16  0.17 
Return On Assets 0.08  0.08 
Return On Equity 0.15  0.14 

Management Efficiency

Eagle Pharmaceuticals has return on total asset (ROA) of 0.0663 % which means that it generated a profit of $0.0663 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0488 %, meaning that it created $0.0488 on every $100 dollars invested by stockholders. Eagle Pharmaceuticals' management efficiency ratios could be used to measure how well Eagle Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Eagle Pharmaceuticals' Return On Tangible Assets are fairly stable compared to the past year. Return On Capital Employed is likely to rise to 0.17 in 2024, whereas Return On Equity is likely to drop 0.14 in 2024. At this time, Eagle Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 262.5 M in 2024, whereas Other Current Assets are likely to drop slightly above 8.2 M in 2024.
Last ReportedProjected for Next Year
Book Value Per Share 16.25  17.06 
Tangible Book Value Per Share 4.88  4.51 
Enterprise Value Over EBITDA 5.29  5.03 
Price Book Value Ratio 1.86  1.77 
Enterprise Value Multiple 5.29  5.03 
Price Fair Value 1.86  1.77 
Enterprise Value346.7 M466.6 M
The analysis of Eagle Pharmaceuticals' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Eagle Pharmaceuticals' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Eagle Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Operating Margin
0.1594
Profit Margin
0.0464
Beta
0.458
Return On Assets
0.0663
Return On Equity
0.0488

Technical Drivers

As of the 19th of June, Eagle Pharmaceuticals shows the Standard Deviation of 5.34, mean deviation of 4.02, and Variance of 28.49. Eagle Pharmaceuticals technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.

Eagle Pharmaceuticals Price Movement Analysis

Execute Study
The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Eagle Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Eagle Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Eagle Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Eagle Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Eagle Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Eagle Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Eagle Pharmaceuticals Predictive Daily Indicators

Eagle Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Eagle Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Eagle Pharmaceuticals Corporate Filings

8K
29th of May 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
22nd of May 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
15th of May 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
10th of May 2024
Other Reports
ViewVerify
8K
12th of April 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
18th of March 2024
Other Reports
ViewVerify
8K
8th of March 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
1st of March 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify

Eagle Pharmaceuticals Forecast Models

Eagle Pharmaceuticals' time-series forecasting models are one of many Eagle Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Eagle Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Eagle Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Eagle Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Eagle shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Eagle Pharmaceuticals. By using and applying Eagle Stock analysis, traders can create a robust methodology for identifying Eagle entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin 0.17  0.18 
Operating Profit Margin 0.15  0.16 
Net Profit Margin 0.10  0.11 
Gross Profit Margin 0.63  0.47 

Current Eagle Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Eagle analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Eagle analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
17.0Strong Buy1Odds
Eagle Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Eagle analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Eagle stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Eagle Pharmaceuticals, talking to its executives and customers, or listening to Eagle conference calls.
Eagle Analyst Advice Details

Eagle Stock Analysis Indicators

Eagle Pharmaceuticals stock analysis indicators help investors evaluate how Eagle Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Eagle Pharmaceuticals shares will generate the highest return on investment. By understating and applying Eagle Pharmaceuticals stock analysis, traders can identify Eagle Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow97.7 M
Long Term Debt56.2 M
Common Stock Shares Outstanding13.1 M
Total Stockholder Equity233.6 M
Total Cashflows From Investing Activities-86.8 M
Tax Provision25.8 M
Quarterly Earnings Growth Y O Y-0.871
Property Plant And Equipment Net1.2 M
Cash And Short Term Investments55.3 M
Cash55.3 M
Accounts Payable19 M
Net Debt7.1 M
50 Day M A4.2639
Total Current Liabilities111.1 M
Other Operating Expenses235.7 M
Non Current Assets Total217.4 M
Forward Price Earnings11.3379
Common Stock Total Equity18 K
Non Currrent Assets Other15.7 M
Stock Based Compensation16.5 M

Additional Tools for Eagle Stock Analysis

When running Eagle Pharmaceuticals' price analysis, check to measure Eagle Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eagle Pharmaceuticals is operating at the current time. Most of Eagle Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eagle Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eagle Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eagle Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.